Samsung Biologics and Biogen Idec Announce Formation of Biosimilars Joint Venture Samsung Bioepis
News Feb 29, 2012
Christopher Hansung Ko, previously Senior Vice President of Samsung Strategic Business Development, has been named the CEO of Samsung Bioepis. The joint venture’s Board of Directors will consist of five directors and one auditor.
The strategic collaboration between Samsung Biologics and Biogen Idec will enable Samsung Bioepis to build the capabilities needed to develop high-quality biosimilars.
Construction of Samsung Bioepis’ research and development center, located at Samsung Biologics’ site in Song-do Incheon, Korea, has started and will be completed by the end of the year.
RELATED ARTICLES
Biomedical Catalyst Award Goes To BioMoti, Pharmidex and Queen Mary University of London
NewsThe grant was awarded under the Biomedical Catalyst funding competition to support preclinical studies of new therapeutic approaches for hard-to-treat tumours including advanced ovarian, triple negative breast and pancreatic cancers.
READ MORE
A New Tactic in the Fight Against Drug-Resistant Infections
News$1 million research grant could lead to life-saving antibiotics.
READ MORE
Concept Life Sciences Appoints New Group Head of Toxicology
NewsAppointment supports growth of the Company and expansion of expertise in integrated drug discovery and development.
READ MOREComments | 0 ADD COMMENT
To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
Login
You must be logged in to post a comment.